Table 4 Statistical analysis for OS and PFS.
Univariate Analysis for Overall Survival (OS) cancer patients with brain metastases | |||
|---|---|---|---|
| Â | OS (months) | 95% C.I. | P value |
Radiological response: | Â | Â | Â |
Tumor control (SD, CR, PR) | 13.00 | 12.35 – 13.65 | < 0.0001 |
Brain progression (PD) | 5.00 | 3.83 – 6.17 |  |
Lung Cancer | 13.00 | 12.10 – 13.90 | 0.9263 |
All the others | 12.00 | 10.32 – 13.68 |  |
Males | 11.00 | 7.63 – 14.37 | 0.239 |
Females | 13.00 | 12.22 – 13.78 |  |
KPS <70 | 5.00 | 2.39 – 7.61 | 0.0006 |
KPS ≥ 70 | 13.00 | 12.37 – 13.63 |  |
No previous chemotherapy | 13.00 | 11.53 – 14.47 | 0.7568 |
Previous chemotherapy | 12.00 | 10.86 – 13.14 |  |
No extracranial disease | 13.00 | 13.19 – 14.81 | 0.0681 |
Extracranial disease | 10.00 | 7.31 – 14.69 |  |
Age > 65 years | 6.00 | 2.56 – 9.23 | 0.0050 |
Age ≤ 65 years | 12.00 | 10.01 – 13.67 |  |
RPA 1 | 13.00 | 11.95 – 14.05 | 0.0025 |
RPA 2 | 13.00 | 12.16 – 13.84 |  |
RPA 3 | 5.00 | 2.39 – 7.61 |  |
Univariate Analysis for Progression Free Survival (PFS) cancer patients with brain metastases | |||
| Â | PFS (months) | 95% C.I. | P value |
Radiological response: | Â | Â | Â |
Tumor control (SD, CR, PR) | 10.00 | 8.54 – 11.46 | < 0.0001 |
Brain progression (PD) | 4.00 | 3.63 – 4.37 |  |
Lung Cancer | 9.00 | 7.85 – 10.15 | 0.3578 |
All the others | 10.00 | 7.67 – 12,33 |  |
Males | 9.00 | 7.42 – 10.58 | 0.4815 |
Females | 9.00 | 6.50 – 11.50 |  |
KPS <70 | 4.00 | 3.22 – 4.78 | 0.0016 |
KPS ≥ 70 | 10.00 | 8.40 – 11.60 |  |
No previous chemotherapy | 10.00 | 8.05 – 11.95 | 0.7835 |
Previous chemotherapy | 8.00 | 6.73 – 9.27 |  |
No extracranial disease | 11.00 | 9.54 – 12.45 | 0.0247 |
Extracranial disease | 8.00 | 5.80 – 10.20 |  |
Age > 65 years | 5.00 | 4.10 – 6.43 | 0.02 |
Age ≤ 65 years | 10.00 | 7.22 – 11.98 |  |
RPA 1 | 11.00 | 8.56 – 13.44 | 0.0027 |
RPA 2 | 9.00 | 7.25 – 10.75 |  |
RPA 3 | 4.00 | 3.22 – 4.78 |  |